|
gptkbp:instanceOf
|
gptkb:chemical_compound
sedative-hypnotic drug
|
|
gptkbp:abusePotential
|
high
|
|
gptkbp:brand
|
gptkb:Mandrax
gptkb:Quaalude
|
|
gptkbp:CASNumber
|
72-44-6
|
|
gptkbp:category
|
gptkb:quinazolinone
recreational drug
central nervous system depressant
withdrawn drug
|
|
gptkbp:chemicalFormula
|
C16H14N2O
|
|
gptkbp:developedBy
|
gptkb:India
|
|
gptkbp:discoveredBy
|
gptkb:Indian_Central_Drugs_Laboratory
gptkb:Indra_Kishore_Kacker
gptkb:Syed_Husain_Zaheer
|
|
gptkbp:eliminationHalfLife
|
20-60 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasStreet
|
lemmon 714
ludes
mandies
sopors
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Methaqualone
|
|
gptkbp:introduced
|
1950s
|
|
gptkbp:IUPACName
|
2-methyl-3-o-tolyl-4(3H)-quinazolinone
|
|
gptkbp:legal_status_in_South_Africa
|
Schedule 6 drug
|
|
gptkbp:legal_status_in_UK
|
Class B drug
|
|
gptkbp:legalStatus
|
Schedule I controlled substance
|
|
gptkbp:mechanismOfAction
|
GABA-A receptor positive allosteric modulator
|
|
gptkbp:meltingPoint
|
113–116 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
250.3 g/mol
|
|
gptkbp:overdoseSymptoms
|
death
coma
|
|
gptkbp:PubChem_CID
|
4166
4023
CHEMBL1201192
|
|
gptkbp:relatedTo
|
gptkb:cloroqualone
etaqualone
mecloqualone
|
|
gptkbp:routeOfAdministration
|
oral
smoked (in combination with cannabis)
|
|
gptkbp:sideEffect
|
addiction
drowsiness
respiratory depression
euphoria
ataxia
|
|
gptkbp:solubility
|
slightly soluble in water
|
|
gptkbp:UNII
|
U77QF4M1GW
|
|
gptkbp:usedFor
|
treatment of insomnia
treatment of anxiety
|
|
gptkbp:withdrawn
|
1980s
widespread abuse
addiction risk
|
|
gptkbp:year_of_patent
|
1951
|
|
gptkbp:bfsParent
|
gptkb:Schedule_I
gptkb:Schedule_I_(US)
|
|
gptkbp:bfsLayer
|
6
|